Results 11 to 20 of about 3,197,416 (181)
Patterns of initiation of second generation antipsychotics for bipolar disorder: a month-by-month analysis of provider behavior [PDF]
, 2014 Background: Several second generation antipsychotics (SGAs) received FDA approval for bipolar disorder in the 2000s. Although efficacious, they have been costly and may cause significant side effects.
Bajor, Laura +7 more
core +5 more sources
The role of NMDA receptors in bipolar disorder: A systematic review
Bipolar Disorders, Volume 25, Issue 8, Page 624-636, December 2023., 2023 Abstract Objectives Glutamatergic transmission and N‐methyl‐D‐aspartate receptors (NMDARs) have been implicated in the pathophysiology schizophrenic spectrum and major depressive disorders. Less is known about the role of NMDARs in bipolar disorder (BD).
Francesco Weiss +6 more
wiley +1 more source
Bipolar Disorders, Volume 25, Issue 7, Page 583-591, November 2023., 2023 Abstract Introduction Antidepressants are commonly used “off‐label” for bipolar depression, despite concerns over the risk of potential treatment‐emergent mania (or “manic switch”). Treatment‐emergent mania is difficult to study with adequate power in clinical trials as it requires a large group of participants and long follow‐up.
Oskar Hougaard Jefsen +2 more
wiley +1 more source
Effects of memantine on mania‐like phenotypes exhibited by Drosophila Shaker mutants
CNS Neuroscience &Therapeutics, Volume 29, Issue 7, Page 1750-1761, July 2023., 2023 Amelioration of functional and metabolic parameters in Drosophila mutant upon memantine treatment. Abstract Introduction Increased glutamate levels and electrolytic fluctuations have been observed in acutely manic patients. Despite some efficacy of the non‐competitive NMDA receptor antagonist memantine (Mem), such as antidepressant‐like and mood ...
Ignazia Mocci +11 more
wiley +1 more source
Bipolar Disorders, Volume 25, Issue 3, Page 221-232, May 2023., 2023 Abstract Background There remain few efficacious treatments for bipolar depression, which dominates the course of bipolar disorder (BD). Despite multiple studies reporting associations between depression and cerebral blood flow (CBF), little is known regarding CBF as a treatment target, or predictor and/or indicator of treatment response, in BD ...
William S. H. Kim +16 more
wiley +1 more source
Case Reports in Psychiatry, Volume 2023, Issue 1, 2023., 2023 First‐line treatments for schizophrenia and schizoaffective disorder include antipsychotics and mood stabilizers, but their use may at times be limited due to severe adverse events. This case describes a 41‐year‐old male with a history of schizoaffective disorder and polysubstance use who was admitted to an inpatient psychiatry unit for acute manic and
David S. Im +3 more
wiley +1 more source
New Therapeutic Targets for Mood Disorders [PDF]
, 2010 Existing pharmacological treatments for bipolar disorder (BPD) and major depressive disorder (MDD) are often insufficient for many patients. Here we describe a number of targets/compounds that clinical and preclinical studies suggest could result in ...
Carlos A. Zarate +8 more
core +1 more source
Antipsychotic switching in bipolar disorders: a systematic review [PDF]
, 2017 With the increasingly widespread use of antipsychotics in bipolar disorder (BD), switching among these agents and between antipsychotics and mood stabilizers has become more common, in particular, since the introduction of the novel atypical ...
Bernardo Arroyo, Miguel +5 more
core +3 more sources
A systematic review and meta‐analysis of treatments for rapid cycling bipolar disorder
Acta Psychiatrica Scandinavica, Volume 146, Issue 4, Page 290-311, October 2022., 2022 Abstract Objectives Rapid cycling is a common and disabling phenomenon in individuals with bipolar disorders. In the absence of a recent literature examination, this systematic review and meta‐analysis aimed to synthesise the evidence of efficacy, acceptability and tolerability of treatments for individuals with rapid cycling bipolar disorder (RCBD ...
Rebecca Strawbridge +6 more
wiley +1 more source
The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease
Clinical and Translational Science, Volume 15, Issue 9, Page 2241-2250, September 2022., 2022 Abstract Obese and overweight children are at risk of developing nonalcoholic fatty liver disease (NAFLD), which can lead to steatohepatitis, cirrhosis, and liver transplantation. Neuropsychiatric conditions affect an increasing proportion of children and often require neuropsychiatric medications (NPMs) that are associated with weight gain and/or drug‐
Jamie L. Ryan +6 more
wiley +1 more source